Immunogenicity to cerliponase alfa, an enzyme replacement therapy for patients with CLN2 disease: results from a phase 1/2 study

被引：0
|
作者：
Cherukuri, Anu [1 ]
Cahan, Heather [1 ]
Van Tuyl, Andrea [1 ]
de Hart, Greg [1 ]
Slasor, Peter [1 ]
Bray, Laurie [1 ]
Henshaw, Josh [1 ]
Ajayi, Temitayo [1 ]
Jacoby, Dave [1 ]
O'Neill, Charles [1 ]
Schweighardt, Becky [1 ]
机构：
[1] BioMarin Pharmaceut Inc, Novato, CA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2017年 / 120卷 / 1-2期
关键词：
D O I：
10.1016/j.ymgme.2016.11.064
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
55
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [21] Cerliponase alfa for the treatment of atypical phenotypes of CLN2 disease: A retrospective case series
    Wibbeler, Eva
    Wang, Raymond
    de los Reyes, Emily
    Specchio, Nicola
    Gissen, Paul
    Guelbert, Norberto
    Nickel, Miriam
    Schwering, Christoph
    Lehwald, Lenora
    Trivisano, Marina
    Lee, Laura
    Amato, Gianni
    Cohen-Pfeffer, Jessica
    Shediac, Renee
    Leal-Pardinas, Fernanda
    Schulz, Angela
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S161 - S162
  • [22] Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
    Specchio, Nicola
    Pietrafusa, Nicola
    Trivisano, Marina
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2020, 16 : 213 - 222
  • [23] Intravitreal Cerliponase alfa for the treatment of CLN2 type Batten Disease related retinal dystrophy: A first in man report of ocular enzyme replacement
    Wawrzynski, James
    Gissen, Paul
    Bowman, Richard
    Bower, Rebecca
    Gan, Chin
    Harding, Louise
    Mortensen, Amanda
    Thompson, Dorothy
    Henderson, Robert
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [24] OCT Biomarkers in Ocular CLN2 Disease in Patients Treated With Intraventricular Enzyme Replacement Therapy
    Huang, Wei Chieh
    Ohnsman, Christina M.
    Atiskova, Yevgeniya
    Falabella, Paulo
    Spitzer, Martin S.
    Schulz, Angela
    Dulz, Simon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (08)
  • [25] LONG-TERM SAFETY AND EFFICACY OF INTRACEREBROVENTRICULAR ENZYME REPLACEMENT THERAPY WITH CERLIPONASE ALFA IN CHILDREN CLN WITH 2 DISEASE: INTERIM RESULTS FROM AN ONGOING MULTICENTER, MULTINATIONAL EXTENSION STUDY
    Specchio, N.
    Schulz, A.
    Gissen, P.
    de los Reyes, E.
    Cahan, H.
    Slasor, P.
    Ajayi, T.
    Jacoby, D.
    EPILEPSIA, 2017, 58 : S32 - S32
  • [26] Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2)
    Ammendolia, Ilaria
    Sframeli, Maria
    Esposito, Emanuela
    Cardia, Luigi
    Noto, Alberto
    Curro, Mariaconcetta
    Calapai, Gioacchino
    De Pasquale, Maria
    Mannucci, Carmen
    Calapai, Fabrizio
    PHARMACEUTICALS, 2024, 17 (11)
  • [27] Novel surgical approach for intraventricular cerliponase alfa enzyme replacement therapy via central venous access device (CVAD) port in neuronal ceroid lipofuscinosis type 2 (CLN2) disease
    Scott Boop
    Dominic Nistal
    Adriel Barrios-Anderson
    W. Bruce Cherny
    Irene J. Chang
    Emily Shelkowitz
    Terry Kho
    Hannah E. Goldstein
    Jason Hauptman
    Child's Nervous System, 2025, 41 (1)
  • [28] Cerliponase alfa for the treatment of CLN2 disease in a patient cohort including children <3 years old
    de los Reyes, E.
    Schulz, A.
    Specchio, N.
    Gissen, P.
    Aylward, S.
    Slasor, P.
    Bondade, S.
    Cohen-Pfeffer, J.
    ANNALS OF NEUROLOGY, 2023, 94 : S141 - S141
  • [29] Persistent Treatment Effect of Cerliponase Alfa in Children with CLN2 Disease: A 3 Year Update from an Ongoing Multicenter Extension Study
    Schulz, A.
    Specchio, N.
    Gissen, P.
    de los Reyes, E.
    Cahan, H.
    Slasor, P.
    Jacoby, D.
    Ajayi, T.
    ANNALS OF NEUROLOGY, 2019, 86 : S29 - S30
  • [30] Cerliponase alfa for the treatment of CLN2 disease in a patient cohort including children < 3 years old
    Schulz, A.
    Specchio, N.
    de los Reyes, E.
    Gissen, P.
    Slasor, P.
    Bondade, S.
    Cohen-Pfeffer, J.
    EPILEPSIA, 2023, 64 : 514 - 515
12345